- Companies
- Enko Chem
Enko Chem Valuation, Funding & Investors
Enko Chem is valued at $320M as of July 2022.
Last Enko Chem valuation
$320M
Series C · Jul 2022
Last Enko Chem funding round
$10M
Series C · Jan 2023
Cumulative funding Enko Chem raised
$135M
across 5 funding rounds
Key investors in Enko Chem
Eight Roads Ventures
Bill & Melinda Gates Foundation
Anterra Capital
Finistere Ventures
Germin8 Ventures
Novalis LifeSciences
About Enko Chem
Enko Chem is a Durham-headquartered crop protection company developing pest control products. The firm employs a proprietary discovery platform for novel chemistries targeting insects and diseases in staple crops. Enko Chem advances sustainable agriculture solutions for row and specialty farming.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$320M (Jul 2022)
Sectors
Enko Chem Valuation
Enko Chem is currently valued at $320M, based on its Series C in July 2022.
The $70M round was led by Nufarm Finance NZ, with participation from Endeavor8, Bill & Melinda Gates Foundation, Novalis LifeSciences, Alumni Ventures, Germin8 Ventures and 6 other investors.
Enko Chem valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jul 2022 | Series C | $320M |
Enko Chem Funding History
Enko Chem has raised a total of $135M across 5 funding rounds.
Enko Chem's first fundraising round was a $8M Series A in July 2018. The most recent completed round was a $10M Series C in January 2023.
Enko Chem funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2023 | Series C | Endeavor8; Castor Ventures; Akroyd LLC; Nufarm Finance NZ; Eight Roads Ventures | $10M | - | Enko Chem is a Connecticut-based agritech firm founded in 2017 that develops crop protection chemistries using a technology platform combining DNA-encoded library screening, machine learning, and structure-based design to address pest resistance, weeds, fungus, and diseases exacerbated by climate change. The company targets global food security challenges by providing targeted solutions for farmers. Enko Chem raised $10 million in a Series C-II extension round on or around December 5, 2022 (approximate to January 2023), from Akroyd LLC, Eight Roads Ventures, Endeavor8, and Nufarm, bringing the total Series C to $80 million and overall funding to $150 million. The funds support advancement of its product pipeline for crop protection. Previous funding includes a $70 million Series C in July 2022. A post-money valuation of $338.64 million is associated with the July 2022 Series C round. |
| Jul 2022 | Series C | Nufarm Finance NZ (lead); Endeavor8; Bill & Melinda Gates Foundation; Novalis LifeSciences; Alumni Ventures; Germin8 Ventures; TO Ventures Food; Rabobank Food & Agri Innovation Fund; Eight Roads Ventures; Anterra Capital; Taher Gozal; Finistere Ventures | $70M | $320M | Enko is a crop health company that uses machine learning-based discovery technology to develop novel crop protection chemistries. Founded in 2017, the company has developed the ENKOMPASS technology platform, which combines DNA-encoded library screening with machine learning and structure-based design to identify new crop protection molecules. Since its inception, Enko has generated hundreds of leading molecules across all categories of crop protection, with its current pipeline led by herbicides demonstrating breakthrough performance compared to industry standards like glyphosate. In July 2022, Enko announced a $70 million Series C funding round led by Nufarm, bringing total capital raised to $140 million. The round included participation from Anterra Capital, Taher Gozal, the Bill & Melinda Gates Foundation, Eight Roads Ventures, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food, Endeavor8, Alumni Ventures Group, and Rabo Food & Agri Innovation Fund. Enko planned to use the new funds to advance its product pipeline and expand the ENKOMPASS platform. The company is also collaborating with major agrochemical companies including Syngenta and Bayer to bring innovative chemistries to market, demonstrating its target-based approach generates industry-leading discoveries in approximately half the time and with fewer resources than conventional R&D methods. |
| Mar 2021 | Seed | Connecticut Innovations | $2M | - | - |
| Jun 2020 | Series B | Bill & Melinda Gates Foundation (lead); Novalis LifeSciences; Germin8 Ventures; Rabobank Food & Agri Innovation Fund; Anterra Capital; Evan Brown; Finistere Ventures | $45M | - | Enko Chem, a Woburn, Massachusetts-based agtech startup founded in 2017, publicly launched from stealth mode on June 26, 2020, after raising $45 million in a Series B funding round led by the Bill & Melinda Gates Foundation. The round included participation from Anterra Capital, Rabo Food & Agri Innovation Fund, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, and TO Ventures Food, bringing the company's total funding to $66 million since inception, with prior seed financing undisclosed beyond a 2018 securities filing indicating $7.5 million raised toward a $15 million target. Incubated by Anterra Capital, Enko leverages pharmaceutical drug discovery technologies, DNA-encoded libraries, predictive analytics, and AI to rapidly develop novel small-molecule crop protection products that target pests and diseases with enhanced safety, lower use rates, and cost-efficiency compared to traditional pesticides. Enko's platform screens billions of compounds against protein targets specific to pests, aiming to revive the stalled R&D pipelines in the $60 billion global crop protection industry hampered by regulatory hurdles, pesticide resistance, and innovation slowdowns. The company is advancing a deep pipeline of novel modes of action toward field testing and regulatory trials, with plans to use the Series B proceeds to expand its technology platform, strengthen core capabilities, and build out product ranges. Strategic board additions include Marijn Dekkers from Novalis LifeSciences and Spencer Maughan from Finistere Ventures. A key focus is partnering with the Gates Foundation to deliver affordable pest-control solutions to smallholder farmers in sub-Saharan Africa and South Asia, regions underserved by current innovations amid climate impacts and food security challenges. CEO Jacqueline Heard, a former Monsanto executive and Anterra venture partner, emphasized building safety measures from the outset to meet future regulatory needs while providing strong returns for farmers. Chief science officer Tom Meade brings experience from Dow AgroSciences. |
| Jul 2018 | Series A | - | $8M | - | Enko Chem raised $7.5 million out of a targeted $15 million in a venture round in July 2018, with Rabobank and Anterra Capital as investors. This preceded its Series B round in 2020, bringing total funding to $66 million. The company, founded in 2017, develops crop protection products using pharmaceutical discovery tools and predictive analytics for safe, cost-efficient solutions against pests and diseases. Enko Chem emerged from stealth in June 2020 with the $45 million Series B led by the Bill & Melinda Gates Foundation, including Anterra Capital, Rabo Food & Agri Innovation Fund, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, and TO Ventures Food. Funds supported advancing its technology platform and pipeline toward field testing and regulatory trials. The company targets the $60 billion crop protection industry with novel modes of action built for safety and sustainability. Later rounds included a $70 million Series C in 2022 led by Nufarm at a $320 million valuation, followed by an additional $10 million in 2023, raising total funding to $150 million. Enko partners with Bayer, Syngenta, and Nufarm, focusing on herbicides outperforming glyphosate and expanding its ENKOMPASS platform combining DNA-encoded libraries, machine learning, and structure-based design. |
Who has invested in Enko Chem?
16 investors have backed Enko Chem across its funding rounds, including Eight Roads Ventures, Bill & Melinda Gates Foundation, Anterra Capital, Finistere Ventures, Germin8 Ventures and Novalis LifeSciences.
Lead investors include Nufarm Finance NZ and Bill & Melinda Gates Foundation.
Enko Chem Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Jul 2022 | ||
| 2 | Lead | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Lead | Jul 2022 | ||
| 2 | Participant | Jul 2022 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 1 | Participant | Jan 2023 | ||
| 1 | Participant | Jan 2023 | ||
| 1 | Participant | Mar 2021 | ||
| 1 | Participant | Jul 2022 | ||
This data is available for Pro users. Sign up to see all 16 Enko Chem investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialEnko Chem Competitors
Enko Chem competitors include listed companies like Itafos, Intrepid Potash, Grupa Azoty and Gurit Holding, and private ones like AKSATA and The Green Coffee Company.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $558M | $189M | $335M | 0.6x | ||
| Publicly listed | $298M | $50M | $531M | 1.3x | ||
| Publicly listed | $3.5B | ($865M) | $532M | 0.9x | ||
| Private | - | - | $320M | - | ||
| Publicly listed | $389M | ($45M) | $320M | 1.0x | ||
| Private | $37M | - | $325M | 8.8x |
Enko Chem Public Comps
Enko Chem is still privately-owned, but its public comps include Gurit Holding, Selena FM, Oxiquim, H&R Gruppe, Orion SA, Alto Ingredients, AB Akola, Camanchaca, Forafric Global and Samyang Holdings.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $389M | ($45M) | 1.0x | 1.0x | (8.8x) | 12.4x | |||
| $475M | $57M | 0.8x | 0.7x | 6.3x | 6.0x | |||
| $248M | $44M | 1.5x | - | 8.7x | - | |||
| $1.4B | $50M | 0.3x | 0.3x | 9.2x | 3.3x | |||
| $1.8B | $159M | 0.7x | 0.7x | 8.1x | 6.2x | |||
| $918M | $49M | 0.4x | 0.4x | 7.6x | 6.4x | |||
| $1.7B | $109M | 0.4x | 0.4x | 7.0x | 6.9x | |||
| $854M | $129M | 0.6x | - | 4.2x | - | |||
This data is available for Pro users. Sign up to see all Enko Chem competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Enko Chem
| When was Enko Chem founded? | Enko Chem was founded in 2017. |
| Where is Enko Chem headquartered? | Enko Chem is headquartered in Stonington, CT, United States. |
| Is Enko Chem publicly listed? | No, Enko Chem is a private, VC-backed company. |
| What is Enko Chem's valuation? | Enko Chem was last valued at $320M in its Series C in July 2022. |
| How much funding has Enko Chem raised? | Enko Chem has raised $135M across 5 funding rounds. |
| What was Enko Chem's last funding round? | Enko Chem's last funding round was a $10M Series C in January 2023. |
| Who are Enko Chem's investors? | Enko Chem's investors include Endeavor8, Bill & Melinda Gates Foundation, Novalis LifeSciences, Germin8 Ventures, Rabobank Food & Agri Innovation Fund, Nufarm Finance NZ, Eight Roads Ventures, Anterra Capital, Finistere Ventures, Castor Ventures and 6 others. |
| Which companies are comparable to Enko Chem? | Companies comparable to Enko Chem include Itafos, Intrepid Potash, Grupa Azoty, AKSATA, Gurit Holding and The Green Coffee Company. |
See companies similar to Enko Chem
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




